Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update

被引：27

作者：

Tumiattit, Vincenzo ^{[1
]}

Bolognesi, Maria Laura ^{[1
]}

Minarini, Anna ^{[1
]}

Rosini, Michela ^{[1
]}

Milelli, Andrea ^{[1
]}

Matera, Riccardo ^{[1
]}

Melchiorre, Carlo ^{[1
]}

机构：

[1] Univ Bologna, Dipartimento Sci Farmaceut, I-40126 Bologna, Italy

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2008年 / 18卷 / 04期

关键词：

acetylcholinesterase; acetylcholinesterase inhibitors; Alzheimer's disease; combinations; donepezil; galantamine; multitarget-directed ligand; rivastigmine; tacrine;

D O I：

10.1517/13543776.18.4.387

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Background: To date, the pharmacotherapy of Alzheimer's disease (AD) has been based on acetylcholinesterase inhibitors (AChEls), and more recently on an N-methyl-D-aspartate receptor antagonist. By increasing acetylcholine concentration in the brain, AChEls slow behavioral and functional impairments, improving cognitive function. Objective: The review provides an update on novel analogs of approved AChEls, their combination with other anti-AD agents, natural AChEls, and modern multitarget-directed ligands (MTDLs) able to hit different biological targets. Methods: We reviewed patents filed during 2005 - 2007 dealing with new AChEls and their potential application for AD treatment. We point out new chemical structures and scaffolds for designing new AD therapeutic agents as well as new combinations or MTDLs. Results and conclusions: Compared to the limited number of novel commercially available AChEl analogs, many new natural compounds were patented for AD treatment. These might represent a starting point for the rational design of new MTDLs.

引用

页码：387 / 401

页数：15

共 50 条

[31] Acetylcholinesterase inhibitors in Alzheimer's disease influence Zinc and Copper homeostasis
Giacconi, R.
Giuli, C.
Casoli, T.
Balietti, M.
Costarelli, L.
Provinciali, M.
Basso, A.
Piacenza, F.
Postacchini, D.
Galeazzi, R.
Fattoretti, P.
Nisi, L.
Fabbietti, P.
Papa, R.
Malavolta, M.
[J]. JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2019, 55 : 58 - 63
[32] Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease?
Small, DH
[J]. TRENDS IN NEUROSCIENCES, 2004, 27 (05) : 245 - 249
[33] Effects of acetylcholinesterase inhibitors on sleep architecture in Alzheimer's disease patients
Loredo, JS
Linn, M
Liu, L
Greenfield, D
Marler, M
Corey-Bloom, J
Ancoli-Israel, S
[J]. SLEEP, 2003, 26 : A349 - A349
[34] Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease
Kaushik, Vinod
Smith, Sarah Toombs
Mikobi, Emmanuel
Raji, Mukaila A.
[J]. AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2018, 33 (02): : 73 - 85
[35] Potential cardioprotective effects of acetylcholinesterase inhibitors in patients with Alzheimer's disease
Rampa, L.
Gaspardone, C.
Fiore, G.
Romagnolo, D.
Cerutti, A.
Santangelo, R.
Magnani, M.
Piscazzi, G.
Sgherzi, G.
Filippi, M.
Margonato, A.
Fragasso, G.
[J]. EUROPEAN HEART JOURNAL, 2023, 44
[36] Antioxidant Enzymatic Activities in Alzheimer's Disease: The Relationship to Acetylcholinesterase Inhibitors
Klugman, Anthony
Naughton, Declan P.
Isaac, Mokhtar
Shah, Iltaf
Petroczi, Andrea
Tabet, Naji
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2012, 30 (03) : 467 - 474
[37] Acetylcholinesterase inhibitors - From nervous gas to Alzheimer's disease therapeutics
Patocka, J
[J]. CHEMICKE LISTY, 1998, 92 (12): : 1016 - 1019
[38] Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors
Sayer, R
Law, E
Connelly, PJ
Breen, KC
[J]. CLINICAL BIOCHEMISTRY, 2004, 37 (02) : 98 - 104
[39] Progress Update: Fluid and Imaging Biomarkers in Alzheimer's Disease
Sutphen, Courtney L.
Fagan, Anne M.
Holtzman, David M.
[J]. BIOLOGICAL PSYCHIATRY, 2014, 75 (07) : 520 - 526
[40] Acetylcholinesterase in Alzheimer's disease
Talesa, VN
[J]. MECHANISMS OF AGEING AND DEVELOPMENT, 2001, 122 (16) : 1961 - 1969

← 1 2 3 4 5 →